272 related articles for article (PubMed ID: 31790428)
21. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
[TBL] [Abstract][Full Text] [Related]
22. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
[TBL] [Abstract][Full Text] [Related]
23. Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018.
du Toit T; Esterhuizen TM; Tiffin N; Abulfathi AA; Reuter H; Decloedt EH
BMC Infect Dis; 2020 Nov; 20(1):900. PubMed ID: 33256634
[TBL] [Abstract][Full Text] [Related]
24. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
Pettipher C; Benitha R
Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
[TBL] [Abstract][Full Text] [Related]
25. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
[TBL] [Abstract][Full Text] [Related]
26. Etanercept therapy in patients with a positive tuberculin skin test.
Manadan AM; Joyce K; Sequeira W; Block JA
Clin Exp Rheumatol; 2007; 25(5):743-5. PubMed ID: 18078624
[TBL] [Abstract][Full Text] [Related]
27. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
28. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
Sánchez-Moya AI; Dauden E
J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
[TBL] [Abstract][Full Text] [Related]
29. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk.
Cagatay T; Bingol Z; Kıyan E; Yegin Z; Okumus G; Arseven O; Erkan F; Gulbaran Z; Erelel M; Ece T; Cagatay P; Kılıçaslan Z
Clin Respir J; 2018 Apr; 12(4):1668-1675. PubMed ID: 29028148
[TBL] [Abstract][Full Text] [Related]
30. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
[TBL] [Abstract][Full Text] [Related]
31. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review.
Sartori NS; de Andrade NPB; da Silva Chakr RM
Clin Rheumatol; 2020 May; 39(5):1439-1447. PubMed ID: 31900748
[TBL] [Abstract][Full Text] [Related]
32. Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents.
Hejazi ME; Ahmadzadeh A; Khabbazi A; Ebrahimi A; Farmani M; Hejazi Y
BMC Infect Dis; 2020 Jul; 20(1):464. PubMed ID: 32615992
[TBL] [Abstract][Full Text] [Related]
33. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
[TBL] [Abstract][Full Text] [Related]
34. Latent tuberculosis infection in patients with rheumatic diseases.
Anton C; Machado FD; Ramirez JMA; Bernardi RM; Palominos PE; Brenol CV; Mello FCQ; Silva DR
J Bras Pneumol; 2019 Apr; 45(2):e20190023. PubMed ID: 31038654
[TBL] [Abstract][Full Text] [Related]
35. Active tuberculosis infection in moroccan patients with rheumatic diseases under biologic therapy: A multicenter national study.
Aachari I; Tahiri L; Elolemy G; Taik FZ; Afilal S; Fellous S; Berkchi JM; Rkain H; Bahiri R; Majjad A; Achemlal L; Ousehal S; Nassar K; Mkinsi O; Mahha FZ; El Aissaoui A; Chaoui I; Harzy T; Youssoufi T; Hassikou H; Kherrab A; Niamane R; Eddarami J; Ichchou L; Ghozlani I; El Bouchti I; Abourazzak FZ; Razine R; Allali F
Int J Mycobacteriol; 2022; 11(2):175-182. PubMed ID: 35775550
[TBL] [Abstract][Full Text] [Related]
36. Disseminated tuberculosis secondary to adalimumab.
Pednekar M; Chandra AB; Chandra PA
Am J Ther; 2012 Jul; 19(4):e139-40. PubMed ID: 20838203
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of interferon-gamma release assay (T-SPOT.TB(™) ) for diagnosis of tuberculosis infection in rheumatic disease patients.
Jiang B; Ding H; Zhou L; Chen X; Chen S; Bao C
Int J Rheum Dis; 2016 Jan; 19(1):38-42. PubMed ID: 26820838
[TBL] [Abstract][Full Text] [Related]
38. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
[TBL] [Abstract][Full Text] [Related]
39. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.
Ai JW; Zhang S; Ruan QL; Yu YQ; Zhang BY; Liu QH; Zhang WH
J Rheumatol; 2015 Dec; 42(12):2229-37. PubMed ID: 26472414
[TBL] [Abstract][Full Text] [Related]
40. TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.
Sargın G; Şentürk T; Ceylan E; Telli M; Çildağ S; Doğan H
Tuberk Toraks; 2018 Jun; 66(2):136-143. PubMed ID: 30246657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
